Amended Current Report Filing (8-k/a)
08 Mayo 2019 - 3:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported): May 1, 2019
MANHATTAN SCIENTIFICS, INC.
(Exact name of registrant as specified in charter)
Delaware
|
|
000-28411
|
|
85-0460639
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
The Chrysler Building
405 Lexington Avenue, 26th Floor
New York, New York, 10174
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, including area code:
(212) 541-2405
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act: Not applicable.
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Not applicable.
|
|
|
EXPLANATORY NOTE: THE SOLE PURPOSE FOR THE FILING OF THIS FORM 8-K/A AMENDING THE FORM 8-K INITIALLY FILED ON MAY 7, 2019 IS TO FILE THE EXHIBITS REFERENCED IN THE EXHIBIT INDEX BELOW UNDER ITEM 9.01.
Item 1.01 Entry Into a Material Definitive Agreement
On May 1, 2019, Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), and Metallicum, Inc., a wholly-owned subsidiary of the Company, entered into an Overarching Agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of three ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
MANHATTAN SCIENTIFICS, INC.
|
|
|
|
|
|
Date: May 8, 2019
|
By:
|
/s/ Emmanuel Tsoupanarias
|
|
New York, New York
|
Name:
|
Emmanuel Tsoupanarias
|
|
|
Title:
|
Chief Executive Officer
|
|
Manhattan Scientifics (PK) (USOTC:MHTX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Manhattan Scientifics (PK) (USOTC:MHTX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024
Real-Time news about Manhattan Scientifics Inc (PK) (OTCMarkets): 0 recent articles
Más de Manhattan Scientifics Inc Artículos de Noticias